0.00
100.00%
-0.9953
Onconova Therapeutics Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.9203 pivot point. If it approaches the $0.606 support level, significant changes may occur.
Previous Close:
$0.9953
Open:
$0
24h Volume:
0
Market Cap:
$20.90M
Revenue:
$226.00K
Net Income/Loss:
$-20.18M
P/E Ratio:
0.00
EPS:
-1
Net Cash Flow:
$-17.40M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
Onconova Therapeutics Inc Stock (ONTX) Company Profile
Name
Onconova Therapeutics Inc
Sector
Industry
Phone
267 759 3680
Address
12 Penns Trail, Newtown, PA
Onconova Therapeutics Inc Stock (ONTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
May-18-21 | Initiated | Guggenheim | Buy |
Mar-01-18 | Reiterated | H.C. Wainwright | Buy |
Jan-17-18 | Downgrade | Maxim Group | Buy → Hold |
Oct-09-17 | Initiated | H.C. Wainwright | Buy |
Apr-27-17 | Initiated | Laidlaw | Buy |
Jul-01-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
May-05-15 | Initiated | H.C. Wainwright | Buy |
View All
Onconova Therapeutics Inc Stock (ONTX) Latest News
Traws Pharma Announces New Employee Inducement Grants
GlobeNewswire Inc.
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
GlobeNewswire Inc.
Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Benzinga
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
Benzinga
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
GlobeNewswire Inc.
Onconova Therapeutics Inc Stock (ONTX) Financials Data
Onconova Therapeutics Inc (ONTX) Revenue 2024
ONTX reported a revenue (TTM) of $226.00 thousand for the quarter ending September 30, 2023, a 0.00% decline year-over-year.
Onconova Therapeutics Inc (ONTX) Net Income 2024
ONTX net income (TTM) was -$20.18 million for the quarter ending September 30, 2023, a -16.62% decrease year-over-year.
Onconova Therapeutics Inc (ONTX) Cash Flow 2024
ONTX recorded a free cash flow (TTM) of -$17.40 million for the quarter ending September 30, 2023, a -4.35% decrease year-over-year.
Onconova Therapeutics Inc (ONTX) Earnings per Share 2024
ONTX earnings per share (TTM) was -$0.97 for the quarter ending September 30, 2023, a -19.75% decline year-over-year.
About Onconova Therapeutics Inc
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Cap:
|
Volume (24h):